Research Reports

Healthcare

icon
Home » Reports » Global Liquid Biopsy Market Analysis Opportunity Outlook 2021
Market Research Report

Global Liquid Biopsy Market Analysis & Opportunity Outlook 2021

Published On : 03:42 AM, 6th February, 2018 REP-ID-69 Category: Healthcare

Liquid biopsy is a non-invasive and simple alternative of conventional surgical biopsies that enable medical professionals to detect cancer causing tumours just by taking the blood sample of the patient. In this manner, liquid biopsy assists the doctors in selecting the correct treatment procedure for patients at right time.

The global liquid biopsy market is anticipated to witness a substantial compound annual growth rate (CAGR) of 25.0% from 2016 to reach USD 10, 850 Million by 2021. Regionally, the global liquid biopsy market is segmented into North America, Latin America, Western and Eastern Europe, Asia-Pacific, Middle East and North Africa (MENA) and Rest of World (Row). 

Market Size and Forecast

Regionally, North America dominates the global liquid biopsy market. It is projected that by 2016 end, 1.7 million new cancer cases would be detected in the U.S. alone, making the country a major market for liquid biopsy in North America.

Western Europe liquid biopsy market is also expected to witness a promising growth sparked by rising cases of lung cancer, which is responsible for 21.5 %of all cancer mortalities in the European region.

Asia-Pacific liquid biopsy market is likely to behold the highest CAGR during the forecast period i.e. 2015-2021. Rising per capita income and increasing investments on healthcare infrastructure are some of the major factors which are projected to bolster liquid biopsy market in countries such as India and China.

Market Segmentation

By Biomarkers

  • Circulating tumour cells (CTCs)
  • Extracellular vesicles (Exosomes)
  • Cell-free circulating DNA (cfDNA)

By Sample Type

  • Blood
  • Urine

By Cancer Type

  • Lung
  • Breast
  • Colorectal
  • Prostate
  • Liver
  • Others

Growth Drivers and challenges

Rising number of cancer patients in the world coupled with innovation in liquid biopsy technology is anticipated to drive the global liquid biopsy market over the forecast period.

In addition to that rising government initiatives to create awareness about cancer detection and treatments is also expected to bolster the global liquid biopsy market in future.

However, expensive medical procedures & cost intensive research process involved in liquid biopsy is anticipated to restrain the development of the global liquid biopsy market over next few years.

Key Players

Global liquid biopsy market includes some of the top players such as NeoGenomics, Biocartis, Guardant Health, Trovagene, Pathway Genomics, etc.Biocept, Inc., Exosome Diagnostics, QIAGEN N.V. Roche Molecular Diagnostics Inc. Bio-Rad Laboratories Inc.

Scope and Context

Overview of the Parent Market

Analyst View

Market Size and Growth

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Western and Eastern Europe (Germany, Italy, Spain, France, U.K, Benelux, Hungary, Rest Of Western Europe, Russia Poland, Rest of Eastern Europe)
  • Asia-Pacific (China, India, Singapore, Japan, Australia & New Zealand & Rest of Asia)
  • Middle East and North Africa (MENA)
  • Rest of World

Segmentation

  • By Technology
  • By Sample Type
  • By Region

Market Dynamics

Supply & Demand Risk

Competitive Landscape

Porter’s Five Force Model

Geographical Economic Activity

Key Players (respective SWOT Analysis) and their Strategies and Product Portfolio

Recent Trends and Developments

Industry Growth Drivers and Challenges

Key Information for Players to establish themselves in current dynamic environment

key Answers

 

               

SELECT LICENSE TYPE

    • "This is an ongoing research and would be delivered in next 15-20 days."
    • Pre-Book now and get receive 10% discount.

KEY BENEFITS

  • DIRECT ANALYST ASSISTANCE

    Direct access to analyst to help you understand the market in a better way to handle your critical question

  • CUSTOMIZE AS PER YOUR NEED

    Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved

  • DISCOUNT ON CUSTOMISATION

    Get 10% free customization

  • QUALITY ASSURED

    Great focus on accuracy and quality of the research

Request for Toc

Call us

(U.S.) - +1 646 586 9123
(Canada) - +1 437 889 3230
(U.K.) - +44 203 608 5919
(India) - + 91 120 660 5495
Email: info@researchnester.com

RELATED REPORTS

Ask The Analyst

Delivery Center

1014, 10th Floor, Tower A1,
Ansal Corporate Park, Plot no 7A/1,
Sector 142 Noida., 201301 India
info@researchnester.com

US Office

1820 Avenue M, Suite# 1113,
Brooklyn, New York 11230
Phone : +1 646 586 9123
info@researchnester.com

Canada (Toronto)

Phone : +1 437 889 3230
info@researchnester.com

UK Office (London)

Phone : +44 203 608 5919
info@researchnester.com

Copyright © 2018 Research Nester. All rights reserved

Top